A citation-based method for searching scientific literature

Sumanta Kumar Pal, Joanne Mortimer. Maturitas 2009
Times Cited: 41







List of co-cited articles
182 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, R Tibshirani, T Aas, S Geisler, H Johnsen, T Hastie, M B Eisen, M van de Rijn, S S Jeffrey,[...]. Proc Natl Acad Sci U S A 2001
31

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2008
31

Triple-negative breast cancer: clinical features and patterns of recurrence.
Rebecca Dent, Maureen Trudeau, Kathleen I Pritchard, Wedad M Hanna, Harriet K Kahn, Carol A Sawka, Lavina A Lickley, Ellen Rawlinson, Ping Sun, Steven A Narod. Clin Cancer Res 2007
29

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
24

Repeated observation of breast tumor subtypes in independent gene expression data sets.
Therese Sorlie, Robert Tibshirani, Joel Parker, Trevor Hastie, J S Marron, Andrew Nobel, Shibing Deng, Hilde Johnsen, Robert Pesich, Stephanie Geisler,[...]. Proc Natl Acad Sci U S A 2003
21

Triple-negative breast cancer--current status and future directions.
O Gluz, C Liedtke, N Gottschalk, L Pusztai, U Nitz, N Harbeck. Ann Oncol 2009
418
21

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
Torsten O Nielsen, Forrest D Hsu, Kristin Jensen, Maggie Cheang, Gamze Karaca, Zhiyuan Hu, Tina Hernandez-Boussard, Chad Livasy, Dave Cowan, Lynn Dressler,[...]. Clin Cancer Res 2004
19

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Lisa A Carey, E Claire Dees, Lynda Sawyer, Lisa Gatti, Dominic T Moore, Frances Collichio, David W Ollila, Carolyn I Sartor, Mark L Graham, Charles M Perou. Clin Cancer Res 2007
19

Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
Roman Rouzier, Charles M Perou, W Fraser Symmans, Nuhad Ibrahim, Massimo Cristofanilli, Keith Anderson, Kenneth R Hess, James Stec, Mark Ayers, Peter Wagner,[...]. Clin Cancer Res 2005
19

Prognostic markers in triple-negative breast cancer.
Emad A Rakha, Maysa E El-Sayed, Andrew R Green, Andrew H S Lee, John F Robertson, Ian O Ellis. Cancer 2007
902
17

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
Kathy Miller, Molin Wang, Julie Gralow, Maura Dickler, Melody Cobleigh, Edith A Perez, Tamara Shenkier, David Cella, Nancy E Davidson. N Engl J Med 2007
17

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
17

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Lisa A Carey, Charles M Perou, Chad A Livasy, Lynn G Dressler, David Cowan, Kathleen Conway, Gamze Karaca, Melissa A Troester, Chiu Kit Tse, Sharon Edmiston,[...]. JAMA 2006
14

Triple-negative breast cancer: therapeutic options.
Susan Cleator, Wolfgang Heller, R Charles Coombes. Lancet Oncol 2007
645
14

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
14

Hallmarks of 'BRCAness' in sporadic cancers.
Nicholas Turner, Andrew Tutt, Alan Ashworth. Nat Rev Cancer 2004
14



High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, Eline van der Burg, Anders O H Nygren, Serge A L Zander, Patrick W B Derksen, Michiel de Bruin, John Zevenhoven, Alan Lau,[...]. Proc Natl Acad Sci U S A 2008
673
12

Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
Bruce G Haffty, Qifeng Yang, Michael Reiss, Thomas Kearney, Susan A Higgins, Joanne Weidhaas, Lyndsay Harris, Willam Hait, Deborah Toppmeyer. J Clin Oncol 2006
781
12

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler,[...]. Lancet 2010
12

Triple negative tumours: a critical review.
J S Reis-Filho, A N J Tutt. Histopathology 2008
652
12

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Deann P Atchley, Constance T Albarracin, Adriana Lopez, Vicente Valero, Christopher I Amos, Ana Maria Gonzalez-Angulo, Gabriel N Hortobagyi, Banu K Arun. J Clin Oncol 2008
378
12

Triple-negative breast cancer: present challenges and new perspectives.
Franca Podo, Lutgarde M C Buydens, Hadassa Degani, Riet Hilhorst, Edda Klipp, Ingrid S Gribbestad, Sabine Van Huffel, Hanneke W M van Laarhoven, Jan Luts, Daniel Monleon,[...]. Mol Oncol 2010
206
12

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Harold J Burstein, Anthony D Elias, Hope S Rugo, Melody A Cobleigh, Antonio C Wolff, Peter D Eisenberg, Mary Lehman, Bonne J Adams, Carlo L Bello, Samuel E DePrimo,[...]. J Clin Oncol 2008
397
9

Poly(ADP-ribose): novel functions for an old molecule.
Valérie Schreiber, Françoise Dantzer, Jean-Christophe Ame, Gilbert de Murcia. Nat Rev Mol Cell Biol 2006
9

BRCA1 dysfunction in sporadic basal-like breast cancer.
N C Turner, J S Reis-Filho, A M Russell, R J Springall, K Ryder, D Steele, K Savage, C E Gillett, F C Schmitt, A Ashworth,[...]. Oncogene 2007
423
9

Basal-like breast cancer: a critical review.
Emad A Rakha, Jorge S Reis-Filho, Ian O Ellis. J Clin Oncol 2008
620
9

Breast cancer classification and prognosis based on gene expression profiles from a population-based study.
Christos Sotiriou, Soek-Ying Neo, Lisa M McShane, Edward L Korn, Philip M Long, Amir Jazaeri, Philippe Martiat, Steve B Fox, Adrian L Harris, Edison T Liu. Proc Natl Acad Sci U S A 2003
9

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.
Bas Kreike, Marieke van Kouwenhove, Hugo Horlings, Britta Weigelt, Hans Peterse, Harry Bartelink, Marc J van de Vijver. Breast Cancer Res 2007
432
9

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C Wolff, M Elizabeth H Hammond, Jared N Schwartz, Karen L Hagerty, D Craig Allred, Richard J Cote, Mitchell Dowsett, Patrick L Fitzgibbons, Wedad M Hanna, Amy Langer,[...]. J Clin Oncol 2007
9

Platinum-based chemotherapy in triple-negative breast cancer.
B Sirohi, M Arnedos, S Popat, S Ashley, A Nerurkar, G Walsh, S Johnston, I E Smith. Ann Oncol 2008
158
9

Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.
Farrah Kassam, Katherine Enright, Rebecca Dent, George Dranitsaris, Jeff Myers, Candi Flynn, Michael Fralick, Ritu Kumar, Mark Clemons. Clin Breast Cancer 2009
292
9

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
Judith Hugh, John Hanson, Maggie Chon U Cheang, Torsten O Nielsen, Charles M Perou, Charles Dumontet, John Reed, Maryla Krajewska, Isabelle Treilleux, Matthieu Rupin,[...]. J Clin Oncol 2009
391
9

Pattern of metastatic spread in triple-negative breast cancer.
Rebecca Dent, Wedad M Hanna, Maureen Trudeau, Ellen Rawlinson, Ping Sun, Steven A Narod. Breast Cancer Res Treat 2009
351
9

Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.
Ana Bosch, Pilar Eroles, Rosa Zaragoza, Juan R Viña, Ana Lluch. Cancer Treat Rev 2010
176
9

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, Xi Chen, Melinda E Sanders, A Bapsi Chakravarthy, Yu Shyr, Jennifer A Pietenpol. J Clin Invest 2011
9

Treatment of triple negative breast cancer (TNBC): current options and future perspectives.
M De Laurentiis, D Cianniello, R Caputo, B Stanzione, G Arpino, S Cinieri, V Lorusso, S De Placido. Cancer Treat Rev 2010
119
9

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
Chad A Livasy, Gamze Karaca, Rita Nanda, Maria S Tretiakova, Olufunmilayo I Olopade, Dominic T Moore, Charles M Perou. Mod Pathol 2006
757
7

Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
Tatsuya Toyama, Hiroko Yamashita, Naoto Kondo, Katsuhiro Okuda, Satoru Takahashi, Hidefumi Sasaki, Hiroshi Sugiura, Hirotaka Iwase, Yoshitaka Fujii. BMC Cancer 2008
59
7

Triple-negative breast cancer: risk factors to potential targets.
Bryan P Schneider, Eric P Winer, William D Foulkes, Judy Garber, Charles M Perou, Andrea Richardson, George W Sledge, Lisa A Carey. Clin Cancer Res 2008
317
7

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, S G Wong, W J Levin, A Ullrich, W L McGuire. Science 1987
7


Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
7

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.
Ana M Mendes-Pereira, Sarah A Martin, Rachel Brough, Afshan McCarthy, Jessica R Taylor, Jung-Sik Kim, Todd Waldman, Christopher J Lord, Alan Ashworth. EMBO Mol Med 2009
478
7

Targeted therapy for cancer using PARP inhibitors.
Christopher J Lord, Alan Ashworth. Curr Opin Pharmacol 2008
212
7

Triple negative breast cancers: clinical and prognostic implications.
S J Dawson, E Provenzano, C Caldas. Eur J Cancer 2009
164
7


Brca1 controls homology-directed DNA repair.
M E Moynahan, J W Chiu, B H Koller, M Jasin. Mol Cell 1999
954
7

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
Richard S Finn, Judy Dering, Charles Ginther, Cindy A Wilson, Padraic Glaspy, Nishan Tchekmedyian, Dennis J Slamon. Breast Cancer Res Treat 2007
318
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.